ATS 2024 was an energizing week for our team. In case we missed you, here are some highlights from our scientific team and academic collaborators:
BEACON Study
|
BEACON Early COPD Analysis PublishedA novel early COPD paper was presented at ATS and is featured on the cover of the AJRCCM (Blue Journal). What: BEACON is an NHS study of very early COPD development in 30-45 year old smokers. |
Select ATS Abstracts
VIDA's analysis was found throughout the show in dozens of scientific sessions and posters, including those directly produced by VIDA and those developed through academic collaborators. Here are some of the highlights.
Mucus Plug Analysis
Mucus plug analysis was a hot topic at ATS and continues to be one of our most popular biomarker categories. VIDA's mucus analysis was featured in 5 ATS abstracts. Our newest development in this area is comprehensive characterization of mucus plugs, including: distribution/location, mucus burden/composition, and regional functional impact, in addition to mucus plug scoring.
|
Proximal Mucus Plug Formation Is Associated With Downstream Air Trapping in Severe Asthma
|
|
|
Reduced Mucus Plugging With Tezepelumab Is Spatially Associated With Reduced Air Trapping in a Broad Population of Patients With Moderate to Severe Asthma Link |
|
|
Persistence of Mucus Plugging in Severe Asthmatics Treated With Biologics Link |
|
Sputum Mucus Rheology, Inflammatory Profile, and CT Mucus Scores in Severe Asthma Link |
|
|
ILD
Imaging biomarkers continue to play a central role in ILD/IPF drug trials. Our mass-based approach to quantifying normal lung tissue garnered attention from ILD therapy providers and researchers. Traditional tissue/texture analysis use volume-based quantification, but we found mass-based measures to be more tightly correlated to clinical tests. Perhaps more importantly, mass-based quantification is more resilient to variability in breath hold effort, allowing for a broader range of scan acquisitions to be used. These new mass-based measures are already included with traditional volume-based measures in our ILD analysis packages.
|
Quantification of Normal Tissue Mass From Computed Tomography in Systemic Sclerosis-associated Interstitial Lung Disease (ILD)Full Poster |
|
Automated Deep Learning-based Airway Count Associates With Lung Function in ILD
|
Asthma and COPD
We are proud to support SARP and SPIROMICS. Notable abstracts from these cohorts were featured in numerous sessions throughout the show.
|
Clinical Characteristics and Longitudinal Outcomes in Heterogeneous Emphysema in SPIROMICS Link |
|
Quantitative Computed Tomography Characteristics of Persistent Airflow Obstruction in Asthma Patients in the Severe Asthma Research Program (SARP) |
|
Indoor Air Pollution, Dysanapsis, and Lung Function Decline: Analyses From the SPIROMICS AIR Study |
Partner Highlights
OSIC
Our CTO, Todd Johnson, gave a live demo of OSIC Cloud at the OSIC Symposium. We are proud to support OSIC's mission of making new discoveries in ILD by leveraging the power of rich imaging and clinical data.
Polarean
Xenon MRI was another hot topic at ATS, with over 30 abstracts. Polarean’s innovative Xenon MRI solution is now integrated into the VIDA Intelligence Platform for trial sponsors. Polarean offers unparalleled quantitative insights into ventilation, gas exchange, microvascular hemodynamics, and alveolar morphology and diffusion. Discover how these biomarkers can enhance your clinical trials, and how VIDA’s platform enables XeMRI at scale.
